What Comphya does

Comphya SA is a Swiss clinical-stage medical device company, spun out of EPFL and headquartered at Innovation Park EPFL in Lausanne, that is developing CaverSTIM™, an implantable neuromodulation system intended to support cavernous nerve function and restore erectile activity in men following radical prostatectomy. The system combines three components: an implantable electrode array placed near the cavernous nerves during prostate cancer surgery, a rechargeable subcutaneous pulse generator implanted in the lower abdomen, and a programmed daily neurostimulation protocol delivered below the sensory threshold during the post-surgical nerve-recovery window. Wireless external programming enables clinicians to adjust stimulation parameters, and the system is designed to integrate into standard nerve-sparing robotic prostatectomy workflows without additional invasive procedures.

The company's primary customer segment is men who experience erectile dysfunction after radical prostatectomy and do not respond to oral PDE5 medications, with a secondary planned segment of spinal cord injury patients with neurogenic ED. Because the device is investigational and not yet approved for commercial use, Comphya currently has no product revenue; its commercialization motion is enterprise-focused, targeting academic medical centers and high-volume urology departments for hospital procurement, with near-term activity centered on clinical trial sites such as Johns Hopkins University School of Medicine (U.S.) and Royal Melbourne Hospital (Australia). Revenue, when generated post-approval, is expected to come from hardware sales of the implantable system and potentially from ongoing programming and monitoring service contracts, distributed through standard medical device supply chains.

Operationally, Comphya is venture-backed, with disclosed cumulative funding of roughly CHF 12.6 million across early grants (Venture Kick, FIT), a CHF 850K convertible loan in January 2023, a CHF 4.35M Series A first tranche in February 2025, and an oversubscribed CHF 7.5M Series A close in July 2025. Leadership combines EPFL-derived research founders with medtech operating veterans from Medtronic, BD, Carefusion, and GE Medical Systems. The company holds an FDA Investigational Device Exemption, completed first-in-human studies in Australia reporting 90% erectile function recovery at nine months with no safety concerns, implanted its first patient in October 2025, and is targeting a pivotal trial in 2026 as the next major value-creating milestone.

Name

Comphya

Legal name

Comphya SA

Website

https://comphya.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Comphya is a Swiss clinical-stage medical device company developing CaverSTIM™, an implantable neuromodulation system intended to restore erectile function in men following radical prostatectomy, with a secondary focus on spinal cord injury patients.

Ownership category

akta.pro rank

Product category

Implantable Neuromodulation Devices

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts) (HLAHAEAD)

akta.pro secondary industries

Reconstructive Urology & Urethral Stricture Care (HLAKAOAH), Neurourology & Voiding Dysfunction (HLAKAOAI)

Keywords

• Implantable neuromodulation devices
• Erectile dysfunction treatment
• Urology medical devices
• Neurostimulation therapy
• Post-prostatectomy care

Headquarters

HQ city

Lausanne

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Implantable Medical Device Sales: Pre-commercial stage company developing an implantable neurostimulation system. Revenue will be generated from device sales to hospitals and surgical centers following regulatory approval. The system includes implantable components (electrode array and pulse generator) that would be procured through standard medical device supply chains.
2. Neuromodulation Therapy System: Complete therapy system including implantable device, subcutaneous pulse generator, and ongoing programming/adjustment services. May include service contracts for device monitoring and programming support.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Comphya is developing CaverSTIM™, an implantable neuromodulation system intended to support cavernous nerve function following radical prostatectomy. The system consists of three integrated components: an implantable electrode array placed during prostate cancer surgery near the cavernous nerves, a small rechargeable subcutaneous pulse generator implanted in the lower abdomen, and a programmed daily neurostimulation protocol delivered below the sensory threshold. It targets the root cause of nerve-related erectile dysfunction during the post-surgical healing window rather than managing symptoms.

Product overview

Comphya offers a single unified product — the CaverSTIM™ Neuromodulation System. This investigational device is an implantable system comprising three integrated components: an implantable electrode array (placed during prostate cancer surgery adjacent to cavernous nerve bundles), a subcutaneous pulse generator (rechargeable unit implanted under the skin in the lower abdomen), and a neuromodulation protocol (programmed daily stimulation routine delivered below the sensory threshold). The system is designed for placement during radical prostatectomy surgery and provides ongoing neurostimulation during the critical nerve recovery window.

Differentiator

Problem solved

Functional benefit

Products and services

• CaverSTIM™ Neuromodulation System

Quantifiable outcome

• 90% erectile function recovery by 9 months in first-in-human study
• +4 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• Johns Hopkins University School of MedicinecoreStrategic or Co-development Partner · 1 January 2024Ongoing pilot clinical trial site for CaverSTIM device in the United States. FDA Investigational Device Exemption (IDE) granted for U.S. clinical evaluation. The trial is assessing safety and efficacy of the implantable neurostimulation system.
• Royal Melbourne HospitalcoreStrategic or Co-development Partner · 1 January 2021First-in-human study completed in Australia at Royal Melbourne Hospital, demonstrating promising early signals with 90% erectile function recovery. Ongoing pilot trials continue at this site. Enhanced clinical trials initiated in Australia following Series A funding.
• EPFL (Swiss Federal Institute of Technology Lausanne)coreStrategic or Co-development Partner · 1 January 2019Comphya was founded as a spin-out from EPFL. The company is based at Innovation Park EPFL. Nikos Stergiopulos, Professor at EPFL and Director of the Laboratory of Hemodynamics and Cardiovascular Technology, serves as Board Member and Co-Founder. The technology is based on research conducted at EPFL.

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Laborie Medical Technologies: Global urology medical device company with diagnostics and therapeutics across the urology care pathway. Comparable as an incumbent in urology device distribution and as a strategic acquirer/platform for emerging urology technologies like CaverSTIM.
• Medtronic: Global neuromodulation leader via its InterStim sacral neuromodulation system for bladder/bowel dysfunction. While addressing a different urologic indication, Medtronic's InterStim is the closest large-scale analog to CaverSTIM's implantable nerve stimulation approach and represents the dominant incumbent Comphya would eventually compete with for hospital neuromodulation infrastructure and reimbursement.
• Coloplast: Established player in male pelvic health via its penile implant (inflatable prosthesis) business for severe ED. Coloplast is the incumbent surgical treatment for ED unresponsive to medication, representing the most direct competitive threat to CaverSTIM's commercial positioning if CaverSTIM reaches the same refractory patient population.
• Boston Scientific (Male Pelvic Health / AMS): Boston Scientific's Male Pelvic Health franchise (formerly American Medical Systems) markets penile implants and urology devices. Comparable as a broad incumbent in male sexual health surgical devices and as a potential strategic acquirer of novel neuromodulation technology.

Direct peers

• Axonics: Pure-play implantable neuromodulation company with sacral and pudendal nerve stimulation systems for incontinence. Axonics is the most directly comparable peer to Comphya in terms of business model (single-platform implantable neurostim), target customer (urology specialists), and go-to-market (hospital-based implantation), though its indication is bowel/bladder rather than sexual dysfunction.

Emerging players

• Valencia Technologies (eCoin): Emerging neuromodulation company with a small, coin-sized implantable tibial nerve stimulator (eCoin) for urinary incontinence. Comparable as a clinical-stage, single-product implantable neuromodulation company targeting urology indications and pursuing similar miniaturization and minimally-invasive implant positioning strategies.
• TheraNova: Early-stage medical device incubator developing novel neuromodulation and minimally invasive therapies. Comparable as an emerging player in novel implantable device development targeting niche urologic or pelvic indications with limited treatment options.
• Stimwave Technologies: Implantable neuromodulation company developing miniaturized, wirelessly powered neurostimulators for multiple indications including urology/pelvic pain. Comparable as a smaller emerging player focused on novel form-factor neuromodulation devices and similar clinical/regulatory pathway.
• Neuspera Medical: Clinical-stage company developing miniaturized, wirelessly powered implantable neuromodulation systems. Comparable as an emerging neuromodulation platform pursuing miniaturized, recharge-free or rechargeable implants and similar regulatory pathway to first-in-class implantable neurostim products.
• Nuelle: Women's sexual health medical device company (Fiera) targeting intimacy and sexual wellness. Comparable thematically as a clinical-stage sexual medicine device company targeting an underserved, low-publicity patient population, although addressing the female rather than male side of sexual health.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/comphya

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds8 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Comphya